ReShape Lifesciences Inc. has entered into a securities purchase agreement to issue a senior secured convertible note worth $833,333.34 and 7,983 shares of common stock to an institutional investor, secured by the company's assets. The note has a 10% interest rate and is due by January 16, 2025, or upon the completion of a merger with Vyome Therapeutics.